CPSE:NOVO BPharmaceuticals
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Pursuing Oral GLP-1 Use In Teen Diabetes
Earlier this month, Novo Nordisk reported positive Phase 3a PIONEER TEENS results showing its oral semaglutide cut HbA1c significantly versus placebo in 10–17-year-olds with type 2 diabetes, and said it plans to seek US and EU label expansions in the second half of 2026.
By opening the door for the first oral GLP-1 therapy in youth-onset type 2 diabetes, Novo Nordisk is targeting a large, under-treated global patient group where current options like metformin and insulin have important...